Tirzepatide has a comparable safety profile to GLP-1RA (54, 70)
Serum GLP-1 levels showed direct proportionality with several metabolic risk markers (that is, body mass index (BMI), leptin, insulin) over 109 men diagnosed with schizophrenia and on clozapine, while this association was not observed in women 131
Industry reporting from Clinical Trials Arena in December 2025 flagged seven additional Phase 3 readouts expected during 2026, which is consistent with a Q4 2026 or Q1 2027 submission target
Synergistic Effects: Combined GLP-1/GIP therapies are being researched for their potential synergistic benefits in weight loss and metabolic control
Inflammation and recovery: hsCRP, ferritin, vitamin D, B12, homocysteine
Do not inject it directly onto the powder, as this can damage the peptide